These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17214578)

  • 1. Type I interferon as a target of treatment in SLE.
    Lee PY; Reeves WH
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):323-30. PubMed ID: 17214578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
    Chyuan IT; Tzeng HT; Chen JY
    Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
    Gallucci S; Meka S; Gamero AM
    Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus.
    Kato Y; Park J; Takamatsu H; Konaka H; Aoki W; Aburaya S; Ueda M; Nishide M; Koyama S; Hayama Y; Kinehara Y; Hirano T; Shima Y; Narazaki M; Kumanogoh A
    Ann Rheum Dis; 2018 Oct; 77(10):1507-1515. PubMed ID: 29945921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I interferon antagonists in clinical development for lupus.
    Paredes JL; Niewold TB
    Expert Opin Investig Drugs; 2020 Sep; 29(9):1025-1041. PubMed ID: 32700979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Cyclin-Dependent Kinase 1 as a Novel Regulator of Type I Interferon Signaling in Systemic Lupus Erythematosus.
    Wu L; Qin Y; Xia S; Dai M; Han X; Wu Y; Zhang X; Ma J; Wang Y; Tang Y; Liu Z; Zhu W; Jallal B; Yao Y; Qu B; Shen N
    Arthritis Rheumatol; 2016 May; 68(5):1222-32. PubMed ID: 26663909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System.
    Hagberg N; Rönnblom L
    Scand J Immunol; 2015 Sep; 82(3):199-207. PubMed ID: 26099519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetics of type I interferon in systemic lupus erythematosus.
    Bronson PG; Chaivorapol C; Ortmann W; Behrens TW; Graham RR
    Curr Opin Immunol; 2012 Oct; 24(5):530-7. PubMed ID: 22889593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural interferon-alpha producing cells in systemic lupus erythematosus.
    Rönnblom L; Alm GV
    Hum Immunol; 2002 Dec; 63(12):1181-93. PubMed ID: 12480262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cause and consequences of the activated type I interferon system in SLE.
    Eloranta ML; Rönnblom L
    J Mol Med (Berl); 2016 Oct; 94(10):1103-1110. PubMed ID: 27094810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Interferon Signature Leads to Increased STAT1/3/5 Phosphorylation in PBMCs From SLE Patients by Single Cell Mass Cytometry.
    Yiu G; Rasmussen TK; Tsai BL; Diep VK; Haddon DJ; Tsoi J; Miller GD; Comin-Anduix B; Deleuran B; Crooks GM; Utz PJ
    Front Immunol; 2022; 13():833636. PubMed ID: 35185925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus.
    Goropevšek A; Holcar M; Avčin T
    Clin Rev Allergy Immunol; 2017 Apr; 52(2):164-181. PubMed ID: 27216430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I interferon pathway in pediatric systemic lupus erythematosus.
    Zhou Y; Song HM
    World J Pediatr; 2024 Jul; 20(7):653-668. PubMed ID: 38914753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease.
    Tanaka Y; Kusuda M; Yamaguchi Y
    Mod Rheumatol; 2023 Aug; 33(5):857-867. PubMed ID: 36440704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.
    Ramaswamy M; Tummala R; Streicher K; Nogueira da Costa A; Brohawn PZ
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic lupus erythematosus and the type I interferon system.
    Rönnblom L; Alm GV
    Arthritis Res Ther; 2003; 5(2):68-75. PubMed ID: 12718746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type I interferon signature in systemic lupus erythematosus.
    Bezalel S; Guri KM; Elbirt D; Asher I; Sthoeger ZM
    Isr Med Assoc J; 2014 Apr; 16(4):246-9. PubMed ID: 24834763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Plasmacytoid Dendritic Cells-Type I Interferon Axis Is Critically Implicated in the Pathogenesis of Systemic Lupus Erythematosus.
    Kim JM; Park SH; Kim HY; Kwok SK
    Int J Mol Sci; 2015 Jun; 16(6):14158-70. PubMed ID: 26110387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.